GleamWall
中文EN

PHIO Phio Pharmaceuticals Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1533040 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-84.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-159.0%
ROA-128.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$3.06M$3.08M$2.79M$1.48M$1.18M$1.07M$886,000$985,000
SG&A expense$1.21M$1.19M$1.37M$1.06M$1.32M$1.24M$986,000$689,000
Operating income-$4.27M-$4.27M-$4.17M-$2.53M-$2.50M-$2.31M-$1.87M-$1.67M
Interest expense——————-$125,000—
Net income-$4.16M-$4.14M-$4.00M-$2.37M-$2.39M-$2.17M-$1.77M-$1.63M
EBITDA-$4.27M-$4.27M-$4.17M-$2.53M-$2.50M-$2.31M-$1.87M-$1.67M
EPS (basic)-0.36-0.36-0.34—-0.44-0.45-0.41—
EPS (diluted)—————-0.45-0.41—
Weighted avg. shares (diluted)—————4.79M4.31M—
Balance sheet
Cash & equivalents$10.61M$13.00M$17.03M$21.03M$10.71M$10.78M$13.28M$5.38M
Current assets$11.31M$14.30M$17.40M$21.48M$11.49M$11.29M$13.44M$5.74M
PP&E, net$7,000$9,000$10,000$11,000$12,000$7,000$4,000$2,000
Total assets$11.32M$14.31M$17.41M$21.49M$11.51M$11.30M$13.44M$5.74M
Current liabilities—————$1.21M$1.27M$1.01M
Total liabilities$2.70M$1.71M$950,000$1.34M$1.67M$1.21M$1.27M$1.01M
Shareholders' equity$8.62M$12.60M$16.46M$20.15M$9.84M$10.10M$12.17M$4.72M
Shares outstanding11.95M11.62M11.62M11.62M5.78M4.80M4.78M1.73M
Cash flow statement
Operating cash flow-$2.28M-$4.04M-$4.00M-$2.08M-$2.08M-$2.54M-$1.27M-$1.37M
Capital expenditure$0$0$0$0$7,000$3,000$2,000$1,000
Free cash flow-$2.28M-$4.04M-$4.00M-$2.08M-$2.09M-$2.54M-$1.28M-$1.37M
Investing cash flow$0$0$3,000$0-$7,000-$3,000-$2,000$8,000
Financing cash flow-$107,000$0$0$12.40M$2.02M$40,000$9.17M$1.35M
Depreciation & amortization$2,000$1,000$1,000$1,000$2,000$0$0$0
Stock-based compensation$285,000$278,000$318,000$274,000$113,000$51,000$43,000$48,000

Free plan shows the latest 8 periods; Pro shows all 62 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.